This video reviews the phase I portion of a trial testing glasdegib in patients with primary/secondary myelofibrosis previously treated with JAK inhibitors.
In this video, Aaron Gerds, MD, of the Cleveland Clinic in Ohio, discusses the phase I portion of a phase I/II trial testing the smoothened (SMO) inhibitor glasdegib in patients with primary/secondary myelofibrosis previously treated with JAK inhibitors.
Gerds gave a presentation on this study (abstract 258) at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9–12 in Atlanta.
Improving Disease Modification and Immune Responses in Myelofibrosis With Pelabresib
November 16th 2024David M. Swoboda, MD, and Andrew Kuykendall, MD, spoke about the current treatment strategies and potential advancements that may improve outcomes such as spleen volume reduction in the myelofibrosis field.